DIOVAN-HCT 25 MG
HYDROCHLOROTHIAZIDE : 25 MG VALSARTAN : 160 MG · DIN 02246955 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is DIOVAN-HCT?
DIOVAN-HCT 25 MG contains HYDROCHLOROTHIAZIDE : 25 MG VALSARTAN : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02246955, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Jan-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIOVAN-HCT used for?
DIOVAN-HCT® (valsartan and hydrochlorothiazide tablets) is indicated for the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. It is not indicated for initial therapy, but may be more convenient if the fixed combination represents the dose and dosing frequency determined by individual titration.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02246955 |
|---|---|
| Brand name | DIOVAN-HCT |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 25 MG VALSARTAN : 160 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09DA03 VALSARTAN AND DIURETICS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Jan-2003 |
How is it administered?
Individualize dosage. Not for initial therapy. Titrate components first. Once stabilized, substitute with fixed combination once daily. Max dose: 320mg valsartan/25mg hydrochlorothiazide.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
2 blister strips of 14 tablets
Contraindications
Hypersensitivity to components or sulfonamides; anuria; severe progressive renal disease; pregnancy/nursing; hyponatremia; hypercalcemia; symptomatic hyperuricemia; concomitant aliskiren use.
Warnings and precautions
Pregnancy: Can cause fetal injury/death. Angioedema; Non-melanoma skin cancer risk; Hypotension; Electrolyte imbalance; Acute Respiratory Distress Syndrome; Acute Angle-Closure Glaucoma.
What can be used instead?
Other Canadian products sharing ATC code C09DA03 VALSARTAN AND DIURETICS. 32 of 63 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-VALSARTAN HCT | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408147 |
| AURO-VALSARTAN HCT | 12.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408120 |
| AURO-VALSARTAN HCT | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408139 |
| AURO-VALSARTAN HCT | 320 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408155 |
| AURO-VALSARTAN HCT | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02408112 |
| DIOVAN-HCT | 12.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02308908 |
| DIOVAN-HCT | 12.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02241900 |
| DIOVAN-HCT | 160 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02241901 |
| DIOVAN-HCT | 25 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02308916 |
| SANDOZ VALSARTAN HCT | 12.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02356694 |
Who else supplies VALSARTAN AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VALSARTAN AND DIURETICS appears in 2425 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.